GALT vs VKTX
GALT: Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer. VKTX: Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
Side-by-side fundamentals
| Metric | GALT | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.50 | $37.31 | |
| Market cap as of 2026-07-23 | $253M | $4.3B | |
| PEG as of 2026-07-23 | n/a | -0.04 | |
| ROE as of 2026-07-23 | -258.6% | -71.3% | VKTX higher |
| ROA as of 2026-07-23 | -164.7% | -65.3% | VKTX higher |
| Debt / equity as of 2026-07-23 | 11.09 | 0.00 | VKTX lower |
| Beta as of 2026-07-23 | 0.36 | 0.65 | |
| 1-year return as of 2026-07-22 close | +22.4% | +16.2% | GALT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.